Raymond Barlow has assumed position as Chief Executive Officer at e-Therapeutics, the drug discovery company.
Barlow, aged 48, was previously Executive Director of Corporate Development at Amgen based in Switzerland.
He brings to e-Therapeutics broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector.
Barlow's previous responsibilities have included scientific, business and corporate roles with AstraZeneca, Crucell NV and Johnson and Johnson.
He said: “e-Therapeutics is at the forefront of a new wave of science and has created a unique, computational-based drug discovery platform. This platform uses a range of truly cutting-edge technologies, including artificial intelligence.”
Having completed a BSc in Chemistry from Leeds University in 1990, Barlow moved to the University of Manchester, from where he gained a PhD in Chemistry in 1994.
He then spent a year at McGill University, Montreal as a post doctoral Fellow before entering the pharmaceutical industry as a senior scientist with Zeneca in Pharmaceutical R and D’s Technology Access and Strategic Alliances team, of which he later became Team Leader in 1998.
Following the merger with Astra, he became a Global Manager in the Discovery and Development function, in-licensing technologies and working on the development of a range of molecules, including those in oncology, cardiovascular, respiratory and inflammatory disease areas.
Upon completion of a year as a Senior Business Analyst, he was appointed Director of Corporate Development, reporting into AstraZeneca’s London HQ.
In this role he was involved in a number of transactions and was part of the team responsible for shaping AstraZeneca’s strategy with the Board, including its move into biologics.
During this period he graduated from Manchester Business School with an MBA and in 2004 he stepped out of the BD function into a Regional commercial leadership role in Brussels covering 14 countries in CEE and Russia.
After 10 years with AstraZeneca , Barlow moved into the biotech sector working in senior business development roles for Microscience Limited and Emergent Solutions.
Barlow then spent five years running his own business (BD Solutions) focused on aiding clients on corporate development and commercialisation projects. At the time he was CEO of Asterion, delivering research deals with Genzyme and Ipsen.
In 2010 he joined Crucell NV and was instrumental in the sale of the business to Johnson and Johnson for whom he worked on a wide range of infectious disease and vaccine deals, before joining Amgen in 2012.
